DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Avapro (Irbesartan) - Summary



When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, AVAPRO should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.



AVAPRO®* (irbesartan) is an angiotensin II receptor (AT1 subtype) antagonist.


AVAPRO (irbesartan) is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Nephropathy in Type 2 Diabetic Patients

AVAPRO is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. In this population, AVAPRO reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) (see CLINICAL PHARMACOLOGY: Clinical Studies).

See all Avapro indications & dosage >>


Published Studies Related to Avapro (Irbesartan)

Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study). [2015]
angiotensin II receptor blocker (ARB) irbesartan... CONCLUSION: Use of the ARB irbesartan as an add-on to other antihypertensive

Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. [2014]
diabetes and nephropathy... CONCLUSIONS: In diabetic individuals with nephropathy, systolic blood pressure

A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. [2011.11.02]
Background Cholesterol and blood pressure lowering therapies are effective in the secondary prevention of ischemic stroke. Aim To determine whether 30 days of treatment with atorvastatin, or irbesartan, initiated within 96 h of symptom onset improves recovery from acute ischemic stroke.Conclusions Treatment with atorvastatin and irbesartan, initiated on day 3 after acute ischemic stroke, did not appear to substantially modify infarct growth.

Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. [2011.11]
BACKGROUND: In vitro and animal experiments have shown inhibiting effects of angiotensin receptor blockers (ARBs) on the formation of advanced glycation end products (AGEs), which are known to be involved in the development of cardiovascular complications in diabetes. However, sufficient human data to confirm such beneficial effects of ARBs on AGEs are lacking. Therefore, we investigated the effects of irbesartan treatment on plasma levels of the AGEs N(epsilon)(1-carboxymethyl)lysine (CML) and N(epsilon)(1-carboxyethyl)lysine (CEL) in hypertensive patients with type 2 diabetes and microalbuminuria... CONCLUSIONS: Long-term irbesartan treatment does not influence plasma levels of the AGE CML and CEL in patients with type 2 diabetes and microalbuminuria.

Role of irbesartan in prevention of post-coronary artery bypass graft atrial fibrillation. [2011.08.01]
BACKGROUND AND OBJECTIVE: Atrial fibrillation (AF) is a common complication of cardiothoracic surgery (CTS). Existing evidence about the potential protective role of angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) for post-CTS AF has been limited and conflicting. In this single-blind, open-label, randomized prospective pilot study, we evaluated the potential protective role of irbesartan (an ARB) in post-coronary artery bypass graft (CABG) AF... CONCLUSION: Pretreatment with irbesartan tends to have a significant protective effect against the occurrence of AF during the post-operative period in patients undergoing CABG.

more studies >>

Clinical Trials Related to Avapro (Irbesartan)

Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans [Recruiting]
The purpose of this study is to test the hypothesis that hypertension increases the anti-natriuretic effects of an angiotensin receptor antagonist during mental stress in overweight/obese AA's who retain sodium during mental stress.

Irbesartan and Adhesion Molecules in AF [Recruiting]
Experimental data suggest that angiotensin II-antagonists reduce the atrial expression of prothrombotic adhesion molecules and oxidative stress parameters. The present study is designed to investigate the effects on angiotensin II-antagonist irbesartan to reduce the amounts of circulating oxidative stress markers and adhesion molecules in patients with persistent atrial fibrillation.

A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin [Completed]

Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF) [Completed]
The main purpose of the study is to compare the mean AERP between treatment groups based on the hypothesis that in subjects with paroxysmal AF, Irbesartan prevents electrophysiological remodeling resulting in a prolonged atrial effective refractory period relative (AERP) to placebo.

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension [Completed]
The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.

more trials >>

Reports of Suspected Avapro (Irbesartan) Side Effects

Loss of Consciousness (28)Blood Pressure Increased (25)Palpitations (23)Dizziness (20)Weight Decreased (18)Blood Count Abnormal (16)Cystitis (16)Burning Sensation (16)Ingrowing Nail (15)Hyperkalaemia (14)more >>


Based on a total of 2 ratings/reviews, Avapro has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.

Avapro review by 58 year old male patient

Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
Treatment Info
Condition / reason:   hypertension
Dosage & duration:   150mg taken once daily for the period of ongoing - has been one year
Other conditions:   none
Other drugs taken:   none
Reported Results
Benefits:   Since I've started the treatment, my tension has stabilized. I've monitored it quite frequently after beginning the treatment to see assess the progress. It seems to also have an impact on my ability to maintain a lower blood pressure than before during physical activities.
Side effects:   None that I've noticed.
Comments:   My doctor has prescribed one tablet daily as an ongoing treatment.


Avapro review by 41 year old female patient

Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
Treatment Info
Condition / reason:   high blood pressure after prewgnancy
Dosage & duration:   150mg taken one a day for the period of on going
Other conditions:   none
Other drugs taken:   none
Reported Results
Benefits:   after being given this treatment there was no coughing no vomitinig like i had experienced with some other bp medication
Side effects:   there were no side effects
Comments:   had blood pressure at 7 month pregnant was taking labetolol after pregnancy tred a few which made me feel ill aprovel makes me feel very well no side effect my blood pressure is now the lowest it has ever been even before i was pregnant

See all Avapro reviews / ratings >>

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017